Notice Regarding Conclusion of Share Transfer Agreement of Kyowa Pharmaceutical Industry Co., Ltd.
[caption id="attachment_9277" align="aligncenter" width="747"]
Press Release[/caption]
Kyowa Pharmaceutical Co., Ltd. (Osaka City, Osaka, President: Reaki Tsunoda, ?Kyowa Pharmaceutical?), Lupin Limited (?Lupine?), Unison Capital No. 4 Investment Limited Partnership and Unison Capital Partners We are pleased to announce that IV (F), LP (hereinafter ?Unison?) has signed a share transfer agreement for Kyowa.?The share transfer is expected to be completed by the end of March 2020.?The partnership between Kyowa Pharmaceutical and Lupine for product development and manufacturing will continue after the transfer of shares.
As a generic manufacturer, Kyowa Pharmaceutical has established itself as a top player, especially in the area of ??the central nervous system (CNS).?In 2016, Shionogi won a long-listed product, and in 2017, launched Astellas' new drug, Bipresso Sustained Release Tablets 50 mg and 150 mg, focusing on the CNS area from generic manufacturers Aiming to become a specialty pharma company, we are promoting transformation.
Through this share transfer, Kyowa Pharmaceutical will provide various solutions that go beyond the pharmaceutical business in collaboration with Unison and its network in the healthcare field (strategic partners such as research institutions, experts, and companies). We aim to grow as a CNS healthcare company that contributes to patients, healthcare professionals, and society.
Press Release[/caption]
Kyowa Pharmaceutical Co., Ltd. (Osaka City, Osaka, President: Reaki Tsunoda, ?Kyowa Pharmaceutical?), Lupin Limited (?Lupine?), Unison Capital No. 4 Investment Limited Partnership and Unison Capital Partners We are pleased to announce that IV (F), LP (hereinafter ?Unison?) has signed a share transfer agreement for Kyowa.?The share transfer is expected to be completed by the end of March 2020.?The partnership between Kyowa Pharmaceutical and Lupine for product development and manufacturing will continue after the transfer of shares.
As a generic manufacturer, Kyowa Pharmaceutical has established itself as a top player, especially in the area of ??the central nervous system (CNS).?In 2016, Shionogi won a long-listed product, and in 2017, launched Astellas' new drug, Bipresso Sustained Release Tablets 50 mg and 150 mg, focusing on the CNS area from generic manufacturers Aiming to become a specialty pharma company, we are promoting transformation.
Through this share transfer, Kyowa Pharmaceutical will provide various solutions that go beyond the pharmaceutical business in collaboration with Unison and its network in the healthcare field (strategic partners such as research institutions, experts, and companies). We aim to grow as a CNS healthcare company that contributes to patients, healthcare professionals, and society.
